82 FR 41149 - Updates to Commission Guidance Regarding Accounting for Sales of Vaccines and Bioterror Countermeasures to the Federal Government for Placement Into the Pediatric Vaccine Stockpile or the Strategic National Stockpile

SECURITIES AND EXCHANGE COMMISSION

Federal Register Volume 82, Issue 166 (August 29, 2017)

Page Range		41149-41151
FR Document		2017-17914

The Securities and Exchange Commission is publishing this interpretive release to update previously issued guidance with respect to accounting for sales of vaccines and bioterror countermeasures to the Federal Government for placement into stockpiles related to the Vaccines for Children Program or the Strategic National Stockpile. This update is being provided to bring existing guidance into conformity with Financial Accounting Standards Board's Accounting Standards Codification Topic 606, Revenue from Contracts with Customers. This guidance is applicable upon a registrant's adoption of Accounting Standards Codification Topic 606 and is applicable to all arrangements for which revenue is recognized in accordance with Accounting Standards Codification Topic 606.

Federal Register, Volume 82 Issue 166 (Tuesday, August 29, 2017)

[Federal Register Volume 82, Number 166 (Tuesday, August 29, 2017)]
[Rules and Regulations]
[Pages 41149-41151]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-17914]


-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

17 CFR Parts 231, 241, and 271

[Release Nos. 33-10403; 34-81429; IC-32785]


Updates to Commission Guidance Regarding Accounting for Sales of 
Vaccines and Bioterror Countermeasures to the Federal Government for 
Placement Into the Pediatric Vaccine Stockpile or the Strategic 
National Stockpile

AGENCY: Securities and Exchange Commission.

ACTION: Interpretation.

-----------------------------------------------------------------------

SUMMARY: The Securities and Exchange Commission is publishing this 
interpretive release to update previously issued guidance with respect 
to accounting for sales of vaccines and bioterror countermeasures to 
the Federal Government for placement into stockpiles related to the 
Vaccines for Children Program or the Strategic National Stockpile. This 
update is being provided to bring existing guidance into conformity 
with Financial Accounting Standards Board's Accounting Standards 
Codification Topic 606, Revenue from Contracts with Customers. This 
guidance is applicable upon a registrant's adoption of Accounting 
Standards Codification Topic 606 and is applicable to all arrangements 
for which revenue is recognized in accordance with Accounting Standards 
Codification Topic 606.

DATES: Effective: August 29, 2017.

FOR FURTHER INFORMATION CONTACT: Kevin L. Vaughn, Senior Associate 
Chief Accountant, or Joseph R. Epstein, Professional Accounting Fellow, 
Office of the Chief Accountant, at (202) 551-5300, U.S. Securities and 
Exchange Commission, 100 F Street NE., Washington, DC 20549-6561. 
Inquiries about this interpretive release also can be directed to 
[email protected].

SUPPLEMENTARY INFORMATION:

I. Introduction

    The Securities and Exchange Commission (``Commission'') continues 
to be committed, as stated in previously-issued guidance (the ``2005 
Release''),\1\ to addressing any unintended consequences of accounting 
requirements that could impair the nation's ability to create and 
maintain sufficient supplies of various vaccines and bioterror 
countermeasures (``enumerated vaccines''). The Commission issued the 
2005 Release to address questions about the timing of revenue 
recognition for vaccines placed into the Vaccines for Children Program 
and the Strategic National Stockpile. At the time of the 2005 Release, 
some expressed concerns that the application of generally accepted 
accounting principles may require revenue recognition to be delayed 
beyond the period in which the vaccine is placed in the stockpile, and 
may have an unintended consequence of causing some vaccine 
manufacturers to decline to participate in these critical stockpile 
programs. The Commission published the guidance in the 2005 Release to 
resolve the accounting questions. With the Financial Accounting 
Standards Board's (``FASB'') issuance of Accounting Standards 
Codification (``ASC'') Topic 606, Revenues from Contracts with 
Customers (``ASC Topic 606''),\2\ we are providing this updated 
guidance.
---------------------------------------------------------------------------

    \1\ See Commission Guidance Regarding Accounting for Sales of 
Vaccines and Bioterror Countermeasures to the Federal Government for 
Placement into the Pediatric Vaccine Stockpile or the Strategic 
National Stockpile, Release No. 33-8642 (Dec. 5, 2005).
    \2\ The International Accounting Standards Board (IASB) has also 
issued IFRS 15, Revenue from Contracts with Customers (IFRS 15). The 
issuance of ASC Topic 606 and IFRS 15 completes the joint effort by 
the FASB and IASB that was undertaken with the intent of improving 
financial reporting by creating converged comprehensive revenue 
recognition guidance for U.S. GAAP and IFRS.
---------------------------------------------------------------------------

    Government vaccine stockpile programs are unique in many respects. 
For example, the primary objective of purchasing the vaccines is not to 
take delivery for ultimate use but rather to be able to require 
immediate delivery on notice. An additional characteristic of vaccine 
stockpiles is the limited shelf life of the vaccines. For these and 
other reasons, the Commission continues to limit this guidance to the 
vaccines enumerated below.

II. The Application of Generally Accepted Accounting Principles for 
Revenue Recognition to Vaccine Stockpiles

    The Commission historically has recognized pronouncements of the 
FASB as authoritative in the absence of any contrary determination by 
the Commission.\3\ In Financial Reporting Release No. 70,\4\ the 
Commission stated its determination that the FASB and its parent 
organization, the Financial Accounting Foundation, satisfied the 
criteria in Section 19(b) of the Securities Act of 1933 \5\ and, 
accordingly, FASB's financial accounting and reporting standards are 
recognized as ``generally accepted'' for purposes of the federal 
securities laws. As a result, registrants are required to comply with 
those standards in preparing financial statements filed with the 
Commission, unless the Commission provides otherwise.\6\
---------------------------------------------------------------------------

    \3\ Rule 4-01(a)(1) of Regulation S-X, 17 CFR 210.4-01(a)(1). 
See Accounting Series Release (``ASR'') No. 150 (Dec. 20, 1973) and 
ASR No. 4 (Apr. 25, 1938).
    \4\ Policy Statement: Reaffirming the Status of the FASB as a 
Designated Private-Sector Standard Setter, Release Nos. 33-8221; 34-
47743; IC-26028; FR-70 (Apr. 25, 2003) (``FR-70''); 68 FR 23333 (May 
1, 2003).
    \5\ 15 U.S.C. 77s(b).
    \6\ See FR-70; Rule 4-01(a)(1) of Regulation S-X, 17 CFR 210.4-
01(a)(1).
---------------------------------------------------------------------------

    Although no specific guidance has been published by the FASB 
related to revenue recognition for vaccine stockpiles, the FASB has 
issued comprehensive revenue recognition guidance in ASC Topic 606, 
which supersedes most previous revenue recognition guidance issued by 
the FASB.
    In response to the new, comprehensive revenue recognition model in 
ASC Topic 606, simultaneous with publication of this release, the 
Commission has issued an interpretation stating \7\ that upon the 
registrant's adoption of ASC Topic 606, such registrant should no 
longer rely on the guidance in Securities Exchange Act Release No. 
23507 and Accounting and

[[Page 41150]]

Auditing Enforcement Release No. 108, In the Matter of Stewart Parness 
(``AAER 108''),\8\ which set forth criteria to be met in order to 
recognize revenue when delivery has not occurred. The Commission staff 
had previously reiterated the guidance in AAER 108 in Staff Accounting 
Bulletin (``SAB'') Topic 13, Revenue Recognition, which the staff is 
modifying as a result of the FASB's issuance of ASC Topic 606.
---------------------------------------------------------------------------

    \7\ Commission Guidance Regarding Revenue Recognition for Bill-
and-Hold Arrangements, Release No. 33-10402 (Aug. 18, 2017).
    \8\ See In the Matter of Stewart Parness, AAER 108 (Aug. 5, 
1986).
---------------------------------------------------------------------------

    Under ASC Topic 606, the general criteria for revenue recognition 
includes identifying the contract(s) with a customer, identifying the 
performance obligations in the contract, determining the transaction 
price, allocating the transaction price to the performance obligations 
in the contract, and recognizing revenue when (or as) the entity 
satisfies a performance obligation by transferring a promised good or 
service to a customer.\9\ A good or service is transferred when (or as) 
the customer obtains control of that good or service and ASC Topic 606 
sets forth indicators of when control has been transferred.\10\
---------------------------------------------------------------------------

    \9\ See ASC paragraph 606-10-05-04.
    \10\ See ASC paragraphs 606-10-25-23 through 25-30.
---------------------------------------------------------------------------

    ASC Topic 606 also provides specific guidance on contracts under 
which an entity bills a customer for a product but the entity retains 
physical possession of the product until it is transferred to the 
customer at a point in time in the future (i.e., a bill-and-hold 
arrangement).\11\ Topic 606 acknowledges that, for some contracts, a 
customer may obtain control of a product even though that product 
remains in an entity's physical possession.\12\ In order to recognize 
revenue in a bill-and-hold arrangement, Topic 606 requires 
consideration of the indicators of when control has been transferred 
and sets forth additional criteria to be met.\13\
---------------------------------------------------------------------------

    \11\ See ASC paragraphs 606-10-55-81 through 55-84.
    \12\ See ASC paragraph 606-10-55-82.
    \13\ See ASC paragraph 606-10-55-83.
---------------------------------------------------------------------------

III. Updated Commission Guidance

    The Commission believes vaccine manufacturers should recognize 
revenue and provide the disclosures required under ASC Topic 606 when 
vaccines are placed into Federal Governmental stockpile programs 
because control of the enumerated vaccines will have been transferred 
to the customer and the criteria to recognize revenue in a bill-and-
hold arrangement under ASC Topic 606 will have been met.
    The following are the enumerated vaccines subject to this release:
     Childhood disease vaccines;
     Influenza vaccines; and
     Other vaccines and countermeasures sold to the Federal 
Government for placement in the Strategic National Stockpile.
    Due to the uniqueness of the vaccine stockpile programs as 
discussed above, this interpretative guidance is not applicable to 
transactions other than the sales of enumerated vaccines by vaccine 
manufacturers.
    Prior to a registrant's adoption of ASC Topic 606, the guidance 
contained in the 2005 Release is still applicable to all arrangements 
for which revenue is recognized.

List of Subjects in 17 CFR Parts 231, 241, and 271

    Accounting, Diseases, Securities, Terrorism.

Amendments to the Code of Federal Regulations

    For the reasons set out in the preamble, the Commission is amending 
title 17, chapter II of the Code of Federal Regulations as set forth 
below:

PART 231--INTERPRETATIVE RELEASES RELATING TO THE SECURITIES ACT OF 
1933 AND GENERAL RULES AND REGULATIONS THEREUNDER

0
1. Part 231 is amended by adding an entry for Release No. 33-10403 at 
the end of the table to read as follows:

----------------------------------------------------------------------------------------------------------------
               Subject                       Release No.                  Date           Fed. Reg. Vol. and page
----------------------------------------------------------------------------------------------------------------
 
                                                  * * * * * * *
Updates to Commission Guidance         33-10403                 Aug. 18, 2017..........  [INSERT Federal
 Regarding Accounting for Sales of                                                        Register CITATION].
 Vaccines and Bioterror
 Countermeasures to the Federal
 Government for Placement into the
 Pediatric Vaccine Stockpile or the
 Strategic National Stockpile.
----------------------------------------------------------------------------------------------------------------

PART 241--INTERPRETATIVE RELEASES RELATING TO THE SECURITIES 
EXCHANGE ACT OF 1934 AND GENERAL RULES AND REGULATIONS THEREUNDER

0
2. Part 241 is amended by adding an entry for Release No. 34-81429 at 
the end of the table to read as follows:

----------------------------------------------------------------------------------------------------------------
               Subject                       Release No.                  Date           Fed. Reg. vol. and page
----------------------------------------------------------------------------------------------------------------
 
                                                  * * * * * * *
Updates to Commission Guidance         34-81429                 Aug. 18, 2017..........  [INSERT Federal
 Regarding Accounting for Sales of                                                        Register CITATION].
 Vaccines and Bioterror
 Countermeasures to the Federal
 Government for Placement into the
 Pediatric Vaccine Stockpile or the
 Strategic National Stockpile.
----------------------------------------------------------------------------------------------------------------


[[Page 41151]]

PART 271--INTERPRETATIVE RELEASES RELATING TO THE INVESTMENT 
COMPANY ACT OF 1940 AND GENERAL RULES AND REGULATIONS THEREUNDER

0
3. Part 271 is amended by adding an entry for Release No. IC-32785 at 
the end of the table to read as follows:

----------------------------------------------------------------------------------------------------------------
               Subject                       Release No.                  Date           Fed. Reg. vol. and page
----------------------------------------------------------------------------------------------------------------
 
                                                  * * * * * * *
Updates to Commission Guidance         IC-32785                 Aug. 18, 2017..........  [INSERT Federal
 Regarding Accounting for Sales of                                                        Register CITATION].
 Vaccines and Bioterror
 Countermeasures to the Federal
 Government for Placement into the
 Pediatric Vaccine Stockpile or the
 Strategic National Stockpile.
----------------------------------------------------------------------------------------------------------------


    By the Commission.

    Dated: August 18, 2017.
Jill M. Peterson,
Assistant Secretary.
[FR Doc. 2017-17914 Filed 8-28-17; 8:45 am]
BILLING CODE 8011-01-P

Federal Register / Vol. 82, No. 166 / Tuesday, August 29, 2017 / Rules and Regulations 41149

Subject Release No. Date Fed. Reg. vol. and page

* * * * * * *
Commission Guidance Regarding Revenue Recognition IC–32784 Aug. 18, 2017 ..................... [INSERT Federal Register CITATION].
for Bill-and-Hold Arrangements.

By the Commission. SUPPLEMENTARY INFORMATION: reasons, the Commission continues to
Dated: August 18, 2017. limit this guidance to the vaccines
I. Introduction
Jill M. Peterson, enumerated below.
Assistant Secretary. The Securities and Exchange
Commission (‘‘Commission’’) continues II. The Application of Generally
[FR Doc. 2017–17913 Filed 8–28–17; 8:45 am] Accepted Accounting Principles for
to be committed, as stated in previously-
BILLING CODE 8011–01–P
issued guidance (the ‘‘2005 Release’’),1 Revenue Recognition to Vaccine
to addressing any unintended Stockpiles
SECURITIES AND EXCHANGE consequences of accounting The Commission historically has
COMMISSION requirements that could impair the recognized pronouncements of the
nation’s ability to create and maintain FASB as authoritative in the absence of
17 CFR Parts 231, 241, and 271 sufficient supplies of various vaccines any contrary determination by the
and bioterror countermeasures Commission.3 In Financial Reporting
[Release Nos. 33–10403; 34–81429; IC–
32785] (‘‘enumerated vaccines’’). The Release No. 70,4 the Commission stated
Commission issued the 2005 Release to its determination that the FASB and its
Updates to Commission Guidance address questions about the timing of parent organization, the Financial
Regarding Accounting for Sales of revenue recognition for vaccines placed Accounting Foundation, satisfied the
Vaccines and Bioterror into the Vaccines for Children Program criteria in Section 19(b) of the Securities
Countermeasures to the Federal and the Strategic National Stockpile. At Act of 1933 5 and, accordingly, FASB’s
Government for Placement Into the the time of the 2005 Release, some financial accounting and reporting
Pediatric Vaccine Stockpile or the expressed concerns that the application standards are recognized as ‘‘generally
Strategic National Stockpile of generally accepted accounting accepted’’ for purposes of the federal
principles may require revenue securities laws. As a result, registrants
AGENCY: Securities and Exchange recognition to be delayed beyond the are required to comply with those
Commission. period in which the vaccine is placed in standards in preparing financial
ACTION: Interpretation. the stockpile, and may have an statements filed with the Commission,
SUMMARY: The Securities and Exchange unintended consequence of causing unless the Commission provides
Commission is publishing this some vaccine manufacturers to decline otherwise.6
interpretive release to update previously to participate in these critical stockpile Although no specific guidance has
issued guidance with respect to programs. The Commission published been published by the FASB related to
accounting for sales of vaccines and the guidance in the 2005 Release to revenue recognition for vaccine
bioterror countermeasures to the Federal resolve the accounting questions. With stockpiles, the FASB has issued
Government for placement into the Financial Accounting Standards comprehensive revenue recognition
stockpiles related to the Vaccines for Board’s (‘‘FASB’’) issuance of guidance in ASC Topic 606, which
Children Program or the Strategic Accounting Standards Codification supersedes most previous revenue
National Stockpile. This update is being (‘‘ASC’’) Topic 606, Revenues from recognition guidance issued by the
provided to bring existing guidance into Contracts with Customers (‘‘ASC Topic FASB.
conformity with Financial Accounting 606’’),2 we are providing this updated In response to the new,
Standards Board’s Accounting guidance. comprehensive revenue recognition
Standards Codification Topic 606, Government vaccine stockpile model in ASC Topic 606, simultaneous
Revenue from Contracts with programs are unique in many respects. with publication of this release, the
Customers. This guidance is applicable For example, the primary objective of Commission has issued an
upon a registrant’s adoption of purchasing the vaccines is not to take interpretation stating 7 that upon the
Accounting Standards Codification delivery for ultimate use but rather to be registrant’s adoption of ASC Topic 606,
Topic 606 and is applicable to all able to require immediate delivery on such registrant should no longer rely on
arrangements for which revenue is notice. An additional characteristic of the guidance in Securities Exchange Act
recognized in accordance with vaccine stockpiles is the limited shelf Release No. 23507 and Accounting and
Accounting Standards Codification life of the vaccines. For these and other
3 Rule 4–01(a)(1) of Regulation S–X, 17 CFR
Topic 606. 210.4–01(a)(1). See Accounting Series Release
1 See Commission Guidance Regarding
DATES: Effective: August 29, 2017. (‘‘ASR’’) No. 150 (Dec. 20, 1973) and ASR No. 4
Accounting for Sales of Vaccines and Bioterror
FOR FURTHER INFORMATION CONTACT: Countermeasures to the Federal Government for (Apr. 25, 1938).
4 Policy Statement: Reaffirming the Status of the
Kevin L. Vaughn, Senior Associate Chief Placement into the Pediatric Vaccine Stockpile or
the Strategic National Stockpile, Release No. 33– FASB as a Designated Private-Sector Standard
Accountant, or Joseph R. Epstein,
sradovich on DSK3GMQ082PROD with RULES3

8642 (Dec. 5, 2005). Setter, Release Nos. 33–8221; 34–47743; IC–26028;
Professional Accounting Fellow, Office 2 The International Accounting Standards Board FR–70 (Apr. 25, 2003) (‘‘FR–70’’); 68 FR 23333 (May
of the Chief Accountant, at (202) 551– (IASB) has also issued IFRS 15, Revenue from 1, 2003).
5 15 U.S.C. 77s(b).
5300, U.S. Securities and Exchange Contracts with Customers (IFRS 15). The issuance
6 See FR–70; Rule 4–01(a)(1) of Regulation S–X,
Commission, 100 F Street NE., of ASC Topic 606 and IFRS 15 completes the joint
effort by the FASB and IASB that was undertaken 17 CFR 210.4–01(a)(1).
Washington, DC 20549–6561. Inquiries with the intent of improving financial reporting by 7 Commission Guidance Regarding Revenue
about this interpretive release also can creating converged comprehensive revenue Recognition for Bill-and-Hold Arrangements,
be directed to oca@sec.gov. recognition guidance for U.S. GAAP and IFRS. Release No. 33–10402 (Aug. 18, 2017).

VerDate Sep<11>2014 18:17 Aug 28, 2017 Jkt 241001 PO 00000 Frm 00005 Fmt 4701 Sfmt 4700 E:\FR\FM\29AUR3.SGM 29AUR3

41150 Federal Register / Vol. 82, No. 166 / Tuesday, August 29, 2017 / Rules and Regulations

Auditing Enforcement Release No. 108, customer at a point in time in the future Due to the uniqueness of the vaccine
In the Matter of Stewart Parness (i.e., a bill-and-hold arrangement).11 stockpile programs as discussed above,
(‘‘AAER 108’’),8 which set forth criteria Topic 606 acknowledges that, for some this interpretative guidance is not
to be met in order to recognize revenue contracts, a customer may obtain control applicable to transactions other than the
when delivery has not occurred. The of a product even though that product sales of enumerated vaccines by vaccine
Commission staff had previously remains in an entity’s physical manufacturers.
reiterated the guidance in AAER 108 in possession.12 In order to recognize Prior to a registrant’s adoption of ASC
Staff Accounting Bulletin (‘‘SAB’’) revenue in a bill-and-hold arrangement, Topic 606, the guidance contained in
Topic 13, Revenue Recognition, which Topic 606 requires consideration of the the 2005 Release is still applicable to all
the staff is modifying as a result of the indicators of when control has been arrangements for which revenue is
FASB’s issuance of ASC Topic 606. transferred and sets forth additional recognized.
Under ASC Topic 606, the general criteria to be met.13
List of Subjects in 17 CFR Parts 231,
criteria for revenue recognition includes III. Updated Commission Guidance 241, and 271
identifying the contract(s) with a
customer, identifying the performance The Commission believes vaccine Accounting, Diseases, Securities,
obligations in the contract, determining manufacturers should recognize revenue Terrorism.
the transaction price, allocating the and provide the disclosures required
under ASC Topic 606 when vaccines are Amendments to the Code of Federal
transaction price to the performance Regulations
obligations in the contract, and placed into Federal Governmental
recognizing revenue when (or as) the stockpile programs because control of For the reasons set out in the
entity satisfies a performance obligation the enumerated vaccines will have been preamble, the Commission is amending
by transferring a promised good or transferred to the customer and the title 17, chapter II of the Code of Federal
service to a customer.9 A good or service criteria to recognize revenue in a bill- Regulations as set forth below:
and-hold arrangement under ASC Topic
is transferred when (or as) the customer PART 231—INTERPRETATIVE
606 will have been met.
obtains control of that good or service RELEASES RELATING TO THE
The following are the enumerated
and ASC Topic 606 sets forth indicators SECURITIES ACT OF 1933 AND
vaccines subject to this release:
of when control has been transferred.10 • Childhood disease vaccines; GENERAL RULES AND REGULATIONS
ASC Topic 606 also provides specific • Influenza vaccines; and THEREUNDER
guidance on contracts under which an • Other vaccines and
entity bills a customer for a product but countermeasures sold to the Federal ■ 1. Part 231 is amended by adding an
the entity retains physical possession of Government for placement in the entry for Release No. 33–10403 at the
the product until it is transferred to the Strategic National Stockpile. end of the table to read as follows:

Subject Release No. Date Fed. Reg. Vol. and page

* * * * * * *
Updates to Commission Guidance Regarding Account- 33–10403 Aug. 18, 2017 ..................... [INSERT Federal Register CITATION].
ing for Sales of Vaccines and Bioterror Counter-
measures to the Federal Government for Placement
into the Pediatric Vaccine Stockpile or the Strategic
National Stockpile.

PART 241—INTERPRETATIVE
RELEASES RELATING TO THE
SECURITIES EXCHANGE ACT OF 1934
AND GENERAL RULES AND
REGULATIONS THEREUNDER
■ 2. Part 241 is amended by adding an
entry for Release No. 34–81429 at the
end of the table to read as follows:

Subject Release No. Date Fed. Reg. vol. and page

* * * * * * *
Updates to Commission Guidance Regarding Account- 34–81429 Aug. 18, 2017 ..................... [INSERT Federal Register CITATION].
ing for Sales of Vaccines and Bioterror Counter-
measures to the Federal Government for Placement
into the Pediatric Vaccine Stockpile or the Strategic
sradovich on DSK3GMQ082PROD with RULES3

National Stockpile.

8 See In the Matter of Stewart Parness, AAER 108 10 See ASC paragraphs 606–10–25–23 through 12 See ASC paragraph 606–10–55–82.
(Aug. 5, 1986). 25–30. 13 See ASC paragraph 606–10–55–83.
9 See ASC paragraph 606–10–05–04. 11 See ASC paragraphs 606–10–55–81 through

55–84.

VerDate Sep<11>2014 18:17 Aug 28, 2017 Jkt 241001 PO 00000 Frm 00006 Fmt 4701 Sfmt 4700 E:\FR\FM\29AUR3.SGM 29AUR3

$Federal Register / Vol. 82, No. 166 / Tuesday, August 29, 2017 / Rules and Regulations 41151 PART 271—INTERPRETATIVE RELEASES RELATING TO THE INVESTMENT COMPANY ACT OF 1940 AND GENERAL RULES AND REGULATIONS THEREUNDER ■ 3. Part 271 is amended by adding an entry for Release No. IC–32785 at the end of the table to read as follows: Subject Release No. Date Fed. Reg. vol. and page * * * * * * * Updates to Commission Guidance Regarding Account- IC–32785 Aug. 18, 2017 ..................... [INSERT Federal Register CITATION]. ing for Sales of Vaccines and Bioterror Counter- measures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile. By the Commission. Dated: August 18, 2017. Jill M. Peterson, Assistant Secretary. [FR Doc. 2017–17914 Filed 8–28–17; 8:45 am] BILLING CODE 8011–01–P sradovich on DSK3GMQ082PROD with RULES3 VerDate Sep<11>2014 18:17 Aug 28, 2017 Jkt 241001 PO 00000 Frm 00007 Fmt 4701 Sfmt 9990 E:\FR\FM\29AUR3.SGM 29AUR3$

Document Created: 2017-08-29 01:58:20
Document Modified: 2017-08-29 01:58:20

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Rules and Regulations
Action		Interpretation.
Dates		Effective: August 29, 2017.
Contact		Kevin L. Vaughn, Senior Associate Chief Accountant, or Joseph R. Epstein, Professional Accounting Fellow, Office of the Chief Accountant, at (202) 551-5300, U.S. Securities and Exchange Commission, 100 F Street NE., Washington, DC 20549-6561. Inquiries about this interpretive release also can be directed to [email protected]
FR Citation		82 FR 41149
CFR Citation		17 CFR 231 17 CFR 241 17 CFR 271
CFR Associated		Accounting; Diseases; Securities and Terrorism